IONS Q1 2020 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$133M-55.1% YoY

Gross Profit

$131M98.1% margin

Operating Income

-$61M-45.8% margin

Net Income

-$40M-29.7% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

-73.0%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$18M

Stock-Based Comp.

$41M

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$1.5B

Stockholders' Equity

$1.4B

Cash & Equivalents

$486M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$133M	$297M	-55.1%
Gross Profit	$131M	$296M	-55.8%
Operating Income	-$61M	$122M	-150.3%
Net Income	-$40M	$84M	-146.9%

Revenue Segments

Commercial

$84M39%

SPINRAZA Royalties

$66M30%

Research and Development Revenue Under Collaborative Agreements

$49M23%

Product

$15M7%

Licensing and Other Royalties

$3M1%